Abstract: The present application relates to arenaviruses expressing prostate cancer-related antigens. In particular, described herein is a modified arenavirus particle which is engineered to carry a heterologous open reading frame (ORF) encoding a prostate cancer-related antigen or an antigenic fragment thereof, wherein the prostate cancer-related antigen is selected from the group consisting of: prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate-specific membrane antigen (PSMA). Also described herein are arenavius genome segments or S segments encoding the prostate cancer-related antigen or an antigenic fragment thereof, cDNA, DNA expression vector, a pharmaceutical composition comprising such an arenavirus particle, methods of generating such an arenavirus particle and treating prostate cancer using such an arenavirus particle, and a kit for such usage.

Abstract: The present application relates generally to cancer treatment strategies using arenavirus particles. The treatment strategies described herein are for treating cancer, including head and neck squamous cell carcinoma, using tri-segmented arenavirus particles encoding a human papillomavirus (HPV) antigen. The treatment strategies described herein can include administration of an immune checkpoint inhibitor.